Trulieve Faces Lawsuit Over Employee Firings in Florida

Dec.14.2022
Trulieve Faces Lawsuit Over Employee Firings in Florida
Trulieve, a multi-state marijuana operator based in Florida, faces a collective lawsuit for allegedly not providing adequate notice prior to employee layoffs.

Trulieve, a multi-state cannabis operator headquartered in Florida, recently terminated some of its employees in Gadsden County. This resulted in affected workers filing a collective lawsuit alleging that the company did not provide sufficient notice before their termination.


Trulieve, a Florida-based cannabis company, operates two cultivation sites in Quincy and a processing plant on Midway Island in Gadsden County. The company has not disclosed the number of employees who have been terminated but has stated that the move is aimed at reducing layoffs as the company continues to grow, according to the Tallahassee Democrat.


According to Trulieve spokesperson Steve Vancore, affected employees have been offered alternative jobs at the company's other factories in Jefferson and Madison counties. Those employees who were ultimately not able to secure another position will receive severance pay.


Vancore informed Democratic lawmakers in Tallahassee that the layoffs ultimately stemmed from Trulieve's acquisition of Harvest Health and Recreation, which is based in Arizona.


We merged and acquired Harvest a year ago," Vancore told the news media. "This was part of our consolidation strategy as we continue to develop in areas of redundancy and inefficiency. When you have 9,000 employees, this is indeed a measure to improve efficiency.


Last week, employees affected by layoffs filed a class-action lawsuit against Trulieve, alleging that the company failed to provide the required Worker Adjustment and Retraining Notification (WARN) Act notice regarding their termination.


According to Democrats in Tallahassee, the lawsuit alleges that if a company lays off "50 or more employees (excluding any part-time employees) at a single worksite within any 30-day period," it must provide a notice under the WARN Act.


According to a report by the Tampa Bay Times, the lawsuit was originally filed by attorney Tiffany Cruz on behalf of Langel O'Neil, who worked at Trulieve's Quincy facility. The plaintiff is seeking monetary compensation equivalent to the total amount of unpaid wages, salaries, commissions, bonuses, accrued vacation pay, accrued sick pay, and other benefits within 60 days after termination. This has been reported in the media.


Trulieve has contested these allegations, according to Tallahassee attorney and partner at Stearns Weaver Miller, Glenn Burhans Jr., who told the news media that Trulieve "has complied with all state and federal laws regarding the reduction of force.


In possible scenarios, Trulieve offers affected employees new positions at the same location or other locations within the area," he told the Tampa Bay Times. "If relocation is not feasible or not accepted, employees will receive severance pay.


In another statement provided to the news media, Trulieve expressed its commitment to the northwest region of Florida and highlighted the construction of a 750,000-square-foot facility in Jefferson County by the company.


According to a statement released by the company to the Tampa Bay Times, Trulieve has approximately 9,000 employees in the United States and is currently hiring for "additional positions in various fields".



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

FDA Appoints Former Tobacco Enforcement Deputy Jessica Zeller as Director as Agency Weighs PMTA Framework Changes
FDA Appoints Former Tobacco Enforcement Deputy Jessica Zeller as Director as Agency Weighs PMTA Framework Changes
The U.S. Food and Drug Administration (FDA) has named Jessica Zeller director of the Center for Tobacco Products' (CTP) Office of Compliance and Enforcement (OCE), effective November 1, 2026. Zeller, the office's inaugural deputy director, returns from medical device manufacturer Edwards Lifesciences with more than 20 years of regulatory and legal experience. The appointment follows CTP leadership changes and adjustments to tobacco regulation. Bret Koplow became permanent CTP director in September; the FDA revised enforcement priorities for unauthorized e-cigarettes and nicotine pouches in May and announced faster PMTA review procedures. On September 28, the agency said it would evaluate changes to the existing PMTA regulatory framework, including potential rulemaking to replace it.
FDA
Oct.20 by 2Firsts Perspectives
Couche-Tard Posts Double-Digit U.S. Same-Store Growth in Other Nicotine Products, Led by Pouches
Couche-Tard Posts Double-Digit U.S. Same-Store Growth in Other Nicotine Products, Led by Pouches
Alimentation Couche-Tard said U.S. same-store sales in its “other nicotine products” category grew at a double-digit rate in the first quarter of fiscal 2027, led by nicotine pouches, while overall U.S. same-store merchandise revenues increased 1.7%. The company also said its Canadian nicotine business continued to face regulatory pressure and illicit-market headwinds. The U.S. performance coincides with Couche-Tard's participation in efforts to reopen Canadian convenience-store access to authorized nicotine pouches, though the company has not established a direct causal link between the two.
Sep.14
Australia Brings in Deloitte to Support Illicit Tobacco and Vape Enforcement Across Data, Processes and Project Delivery
Australia Brings in Deloitte to Support Illicit Tobacco and Vape Enforcement Across Data, Processes and Project Delivery
Australia’s Department of Home Affairs has hired Deloitte to provide data analytics, business-process, communications and project-delivery support to the Office of the Illicit Tobacco and E-Cigarette Commissioner. The government says Deloitte personnel do not provide policy advice to the Commissioner or the Australian government, with policy development and decision-making remaining with public officials. The arrangement has nevertheless drawn scrutiny because Deloitte has previously provided professional services to several tobacco and vaping companies.
Sep.03
Reynolds Showcases Vuse Pro Flavors and VELO Nicotine Pouches at NACS Show 2026
Reynolds Showcases Vuse Pro Flavors and VELO Nicotine Pouches at NACS Show 2026
Reynolds American, a BAT subsidiary, showcased four Vuse Pro flavored e-cigarette pods and its VELO nicotine pouch portfolio at NACS Show 2026. Booth staff confirmed to 2Firsts that the Vuse Pro flavors are sold in the U.S., although they have not received FDA marketing authorization. BAT outlined plans to expand Vuse retail distribution and reported that VELO held a 30.5% year-to-date volume share of the U.S. modern oral nicotine category through August 2026. The booth also featured the newly launched VELO MAX range and merchandising displays combining cigarettes, vaping products and oral nicotine brands.
EXPO
Oct.09
NAS 2026 | Former FDA Tobacco Chief Mitch Zeller Calls for Shift From “End Game” to “End State”
NAS 2026 | Former FDA Tobacco Chief Mitch Zeller Calls for Shift From “End Game” to “End State”
At the 2026 New Approaches Summit in New York, former FDA Center for Tobacco Products Director Mitch Zeller called for the tobacco harm reduction debate to shift from the traditional “end game” toward defining a desired “end state.” He also highlighted unresolved concerns around dual use, argued that biomarkers of exposure may be more meaningful than cigarettes-per-day in assessing risk reduction, and said nicotine misperceptions remain a major barrier to public health progress.
Sep.25
FDA Authorizes 24 VELO Nicotine Pouches, Increasing U.S. Authorized Total by 56%
FDA Authorizes 24 VELO Nicotine Pouches, Increasing U.S. Authorized Total by 56%
The U.S. FDA authorized 24 VELO nicotine pouch products from a British American Tobacco subsidiary, raising the total number of authorized products from 43 to 67, a 55.8% increase. The newly authorized 4 mg products include lime and passion fruit flavors and feature certified child-resistant packaging. VELO's first FDA marketing authorization adds BAT to a list previously limited to PMI and Altria products, while bringing the agency's nicotine pouch review pilot total to 47 authorized products.
Oct.30